Literature DB >> 32090256

Understanding innate immune response in glioblastoma in search of a way forward.

Ayush Pant1, Michael Lim.   

Abstract

Entities:  

Keywords:  T cells; checkpoint blockade; glioblastoma; immunosuppressive macrophages

Mesh：

Substances：

Year:  2020        PMID： 32090256      PMCID： PMC7158638          DOI： 10.1093/neuonc/noaa038

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

Authors:  K Schumacher; W Haensch; C Röefzaad; P M Schlag
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Authors:  Kurt A Schalper; Maria E Rodriguez-Ruiz; Ricardo Diez-Valle; Alvaro López-Janeiro; Angelo Porciuncula; Miguel A Idoate; Susana Inogés; Carlos de Andrea; Ascensión López-Diaz de Cerio; Sonia Tejada; Pedro Berraondo; Franz Villarroel-Espindola; Jungmin Choi; Alfonso Gúrpide; Miriam Giraldez; Iosune Goicoechea; Jaime Gallego Perez-Larraya; Miguel F Sanmamed; Jose L Perez-Gracia; Ignacio Melero
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

Review 3.  Harnessing innate immunity in cancer therapy.

Authors:  Olivier Demaria; Stéphanie Cornen; Marc Daëron; Yannis Morel; Ruslan Medzhitov; Eric Vivier
Journal:  Nature       Date:  2019-10-02       Impact factor: 49.962

4.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Authors:  Paulo C Rodriguez; David G Quiceno; Jovanny Zabaleta; Blair Ortiz; Arnold H Zea; Maria B Piazuelo; Alberto Delgado; Pelayo Correa; Jason Brayer; Eduardo M Sotomayor; Scott Antonia; Juan B Ochoa; Augusto C Ochoa
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

5.  Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

Authors:  John de Groot; Marta Penas-Prado; Kristin Alfaro-Munoz; Kathy Hunter; Be Lian Pei; Barbara O'Brien; Shiao-Pei Weathers; Monica Loghin; Carlos Kamiya Matsouka; W K Alfred Yung; Jacob Mandel; Jimin Wu; Ying Yuan; Shouhao Zhou; Gregory N Fuller; Jason Huse; Ganesh Rao; Jeffrey S Weinberg; Sujit S Prabhu; Ian E McCutcheon; Frederick F Lang; Sherise D Ferguson; Raymond Sawaya; Rivka Colen; Shalini S Yadav; Jorge Blando; Luis Vence; James Allison; Padmanee Sharma; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

6.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Authors:  Nicholas Butowski; Howard Colman; John F De Groot; Antonio M Omuro; Lakshmi Nayak; Patrick Y Wen; Timothy F Cloughesy; Adhirai Marimuthu; Sam Haidar; Arie Perry; Jason Huse; Joanna Phillips; Brian L West; Keith B Nolop; Henry H Hsu; Keith L Ligon; Annette M Molinaro; Michael Prados
Journal:  Neuro Oncol       Date:  2015-10-08       Impact factor: 12.300

7.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

Authors:  K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

8.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

Authors:  Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

9.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

10.  Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.

Authors:  Laura Strauss; Mohamed A A Mahmoud; Jessica D Weaver; Natalia M Tijaro-Ovalle; Anthos Christofides; Qi Wang; Rinku Pal; Min Yuan; John Asara; Nikolaos Patsoukis; Vassiliki A Boussiotis
Journal:  Sci Immunol       Date:  2020-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.